Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage iii non-small cell lung cancer

44Citations
Citations of this article
24Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Pemetrexed has emerged as one of the most active agents for the treatment of patients with advanced non-small cell lung cancer (NSCLC). We conducted a phase II study to assess the efficacy and feasibility of integrating pemetrexed in a concurrent therapy plan for patients with stage III NSCLC. Methods: Patients with stage III NSCLC with performance status 0 to 1, adequate organ function including pulmonary function, and V20 less than 40% were eligible. Patients were treated with cisplatin 75 mg/m2 (first five patients 60 mg/m2) and pemetrexed 500 mg/m2 every 21 days for three cycles with chest radiotherapy to 66 Gy. Patients then received three cycles of docetaxel 75 mg/m every 21 days. Tumors were analyzed for Excision Repair Cross Complementation Group 1 and thymidylate synthase. Results: Patient characteristics (N = 28) were median age, 60; males, 68%; stage IIIB, 64%; and squamous cell, 43%. Twenty-four patients (86%) completed all three cycles of cisplatin/pemetrexed. Of the 24 patients eligible for docetaxel, 21 (87%) received it. Grade 3/4 toxicities were neutropenia (39%), febrile neutropenia (14%), esophagitis (14%), and pneumonitis (4%). Median survival was 34 months, and 1-year survival was 66%. Survival was not significantly different in squamous and other histology patients. Tumor analysis in 16 patients showed that moderate/strong expression of thymidylate synthase was significantly associated with progression-free survival and overall survival. Conclusion: Integrating pemetrexed in a concurrent therapy regimen for patients with stage III NSCLC is feasible and was associated with a median survival of 34 months. Copyright © 2011 by the International Association for the Study of Lung Cancer.

Author supplied keywords

Cite

CITATION STYLE

APA

Gadgeel, S. M., Ruckdeschel, J. C., Patel, B. B., Wozniak, A., Konski, A., Valdivieso, M., … Turrisi, A. (2011). Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage iii non-small cell lung cancer. Journal of Thoracic Oncology, 6(5), 927–933. https://doi.org/10.1097/JTO.0b013e3182156109

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free